AI Biotech Enveda Doubles in Value to $2 Billion

Backed by a former J&J CEO, the startup plans to advance its drug candidates into late-stage trials.

Discover more from RealUS.news

Subscribe now to keep reading and get access to the full archive.

Continue reading